Published in Vaccine on August 28, 2015
DNA-launched live-attenuated vaccines for biodefense applications. Expert Rev Vaccines (2016) 0.78
Replicon RNA Viral Vectors as Vaccines. Vaccines (Basel) (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology (1997) 3.62
Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol (2000) 2.67
Prostate cancer screening and the management of clinically localized disease. BMJ (2013) 2.45
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest (2002) 2.09
Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol (1997) 1.73
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest (2010) 1.71
A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol (1996) 1.68
Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol (2001) 1.66
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer (2004) 1.45
Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res (2008) 1.41
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett (2005) 1.29
In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res (2007) 1.16
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res (2013) 1.16
Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res (2005) 1.14
Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 1.12
Alphavirus vectors for cancer therapy. Virus Res (2010) 1.06
Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother (2008) 0.98
Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol (2007) 0.98
Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer (2001) 0.97
Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther (2001) 0.96
Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen. Clin Cancer Res (2005) 0.96
Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine (2007) 0.95
Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol (2012) 0.93
Prostate cancer vaccines in combination with additional treatment modalities. Immunol Res (2014) 0.93
A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res (2007) 0.93
A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J Immunother (2012) 0.92
Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol (2011) 0.91
Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model. Breast Cancer Res Treat (2003) 0.91
Virulent and attenuated mutant Venezuelan equine encephalitis virus show marked differences in replication in infection in murine macrophages. Microb Pathog (1996) 0.90
Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer Immunol Immunother (2012) 0.88
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine (2012) 0.87
Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther (2005) 0.85
Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection. J Immunol (2009) 0.85
Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats. PLoS One (2008) 0.84
Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. Oncoimmunology (2014) 0.81
Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor. PLoS One (2011) 0.80
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer Immunol Res (2014) 0.80
Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. Prostate (2014) 0.80
A human dendritic cell subset receptive to the Venezuelan equine encephalitis virus-derived replicon particle constitutively expresses IL-32. J Immunol (2008) 0.79
Immunostimulatory early phenotype of tumor-associated macrophages does not predict tumor growth outcome in an HLA-DR mouse model of prostate cancer. Cancer Immunol Immunother (2015) 0.79